Alex Therapeutics
Alex Therapeutics is a Stockholm-based digital therapeutics company that builds AI-powered CBT/ACT companion apps for pharmaceutical partners, addressing medication adherence, anxiety, and behavior change across oncology, rare disease, addiction, and chronic conditions.
- Company typePrivate
- Founded2018
- HeadquartersStockholm, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Alex Therapeutics does
Alex Therapeutics AB is a Stockholm-based digital therapeutics company founded in 2018 that develops AI-powered Software as a Medical Device (SaMD) products combining evidence-based psychology — primarily Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) — with machine learning to create personalized prescription digital therapeutics and companion apps. Its core technology is the Alex DTx Platform, a modular development environment that enables rapid customization of therapy companions for specific patient populations and drug franchises. On top of this platform the company has built multiple branded products: Almee (a 9-week digital CBT for anxiety in pulmonary fibrosis patients, co-developed with Vicore Pharma and holding FDA Breakthrough Device Designation), Eila (a 12-week nicotine addiction digital therapeutic co-developed with Pfizer for the German market), Florens (a white-label medication management and wellness companion app), Levilog (a CE-marked Parkinson's disease companion app co-developed with Navamedic and distributed with Orion Pharma), and Alex AI — Quit Smoking (an AI-coach-driven cessation program with ~100,000 global users).
The company operates a B2B enterprise model, licensing and co-developing its platform and products with pharmaceutical partners who distribute the digital therapeutics alongside their drugs — including through reimbursement pathways such as Germany's DiGA. Target indications span addiction, mental health comorbidities, oncology, and rare diseases, where complex treatment regimens create high demand for adherence and behavioral support. Revenue is generated through development partnerships, clinical validation support, and commercialization agreements rather than direct consumer pricing, with public pricing undisclosed. The company has raised approximately €4.75M in total disclosed funding across pre-seed and seed rounds, is ISO 27001 certified, and has experience navigating both FDA and CE-marking regulatory processes. Its primary strategic customer relationships are with Pfizer, Vicore Pharma, Navamedic, Orion Pharma, and Merck.
Alex Therapeutics firmographics
Firmographics- Name
- Alex Therapeutics
- Legal name
- Alex Therapeutics AB
- Website
- https://alextherapeutics.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Alex Therapeutics is a Stockholm-based digital therapeutics company that builds AI-powered CBT/ACT companion apps for pharmaceutical partners, addressing medication adherence, anxiety, and behavior change across oncology, rare disease, addiction, and chronic conditions.
- Ownership category
- akta.pro rank
Alex Therapeutics industry classification
Industry- Product category
- Digital Therapeutics
- NAICS
- Software Publishers (513210), Scientific Research and Development Services (5417)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)
- akta.pro secondary industries
- Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI), Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD)
Keywords
Where Alex Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Alex Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Platform Licensing to Pharma Partners: Alex Therapeutics licenses its DTx platform and developed products to pharmaceutical companies. Partners include Pfizer (nicotine addiction), Vicore Pharma (pulmonary fibrosis anxiety), and Navamedic (Parkinson's). Revenue generated through development partnerships, clinical validation support, and commercialization agreements.
- Digital Therapeutic Products: Prescription digital therapeutics developed and commercialized, either standalone or alongside pharmaceutical partner drugs. Products include Almee for anxiety, Eila for nicotine addiction, and Florens for general medication management. Clinically validated and approved medical devices prescribed by doctors.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Alex Therapeutics product offering
Product offeringCore offering
Alex Therapeutics develops and licenses an AI-powered digital therapeutics platform (the Alex DTx Platform) that combines evidence-based psychology — primarily Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) — with artificial intelligence and machine learning to deliver personalized Software as a Medical Device (SaMD) products. The company co-develops prescription digital therapeutics and companion apps with pharmaceutical partners such as Pfizer, Vicore Pharma, and Navamedic, focused on medication adherence, anxiety, nicotine cessation, Parkinson's, pulmonary fibrosis, and other cancer/rare-disease indications. Revenue is generated through B2B licensing, co-development, and commercialization agreements rather than direct-to-consumer sales.
Product overview
Alex Therapeutics is a Stockholm-based digital therapeutics company that operates a modular platform-plus-products architecture. The core of the offering is the Alex DTx Platform, an AI-powered SaMD development platform that combines evidence-based psychology (CBT and ACT) with AI and machine learning to create personalized prescription digital therapies. On top of this platform, the company has developed multiple distinct branded products: Almee (a 9-week digital CBT therapy for anxiety in pulmonary fibrosis patients, developed with Vicore Pharma); Eila (a 12-week nicotine addiction digital therapeutic developed with Pfizer for Germany); Florens (a white-label medication management and wellness companion app); Levilog (a CE-marked companion app for Parkinson's disease developed with Navamedic); and Alex AI - Quit Smoking (an AI-powered smoking cessation program). The company partners with pharmaceutical companies to customize and license these products, positioning itself as the go-to digital health partner for pharma in oncology and rare diseases.
Differentiator
Problem solved
Functional benefit
Brands
- Almee: Digital therapeutic app providing CBT-based treatment for anxiety in patients with pulmonary fibrosis. Received FDA Breakthrough Device Designation.
- Florens
- Eila
- Levilog
Products and services
- Alex DTx Platform AI-powered digital therapeutics development platform combining evidence-based psychology (CBT and ACT) with artificial intelligence and machine learning to enable personalized prescription digital therapies for pharmaceutical partners. Sold/co-developed with pharma companies.
- Almee 9-week prescription digital therapeutic delivering CBT for anxiety symptoms in patients with pulmonary fibrosis. Clinically validated in a 108-participant RCT showing a statistically significant 2.7-point improvement in GAD-7 anxiety scores; received FDA Breakthrough Device Designation. Co-developed with Vicore Pharma.
- Eila 12-week prescription digital therapeutic for tobacco dependence based on Acceptance and Commitment Therapy (ACT) rooted in CBT, co-developed with Pfizer for the German market. Underwent clinical trial with approximately 1,000 participants.
Quantifiable outcome
- 2.7-point statistically significant improvement in GAD-7 anxiety scores compared to control in RCT
- +4 more outcomes
Companies that use Alex Therapeutics
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles1 record
Alex Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Alex Therapeutics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and core.
- Orion PharmaminorNordic pharmaceutical company partner for European expansion of Levilog app through collaboration with Navamedic.
- NavamediccoreExclusive agreement for development of companion app (Levilog) for Parkinson's disease treatment. App is Class 1 CE-marked medical device working with Flexilev medication and OraFID dose dispenser. Available in Nordic countries with European expansion planned through Orion Pharma.
- Hans-Peter FrankcoreAppointed new Chair of Alex Therapeutics Board, bringing experience from Pharma, Medtech and BioTech industries.
- Paul Kirchmeier (as COO)coreNew COO joining from NuvoAir with experience in virtual care software, decentralized trials, and pharma partnerships in US and Europe.
- PfizercoreStrategic commercial partnership to provide evidence-based, clinically validated, personalized digital therapies to patients. Initial focus on Germany for nicotine addiction digital therapeutic (Eila). Pfizer conducting extensive clinical trial in Germany to validate medical benefits.
- Public Health Foundation of India (PHFI)minorCollaborative partnership funded by Vinnova to adapt and clinically validate AI-based tobacco cessation treatment for Indian market. PHFI leads clinical research and recruits test users.
- Vicore PharmacoreCo-development and commercialization of clinically validated digital therapeutic (Almee) providing CBT for patients with idiopathic pulmonary fibrosis. Vicore has exclusive license to commercialize Almee starting in US.
- MerckminorPharmaceutical partner logo displayed on website indicating partnership relationship.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Alex Therapeutics competitors and assessment
Company assessmentEmerging players
- Limbic: UK-based digital mental health company building AI-driven CBT interventions with NHS partnerships. Comparable on AI-personalized CBT therapy and clinical evidence positioning.
- BehaVR: Digital therapeutics company developing FDA-regulated, evidence-based VR therapies for mental and behavioral health. Comparable as a fellow SaMD player using technology-driven personalized therapy for mental health comorbidities.
- Pear Therapeutics (legacy): Historic US leader in prescription digital therapeutics that pioneered FDA-cleared DTx across addiction, psychiatry, and oncology support. Useful prior-art peer for understanding the prescription DTx category, though now restructured.
Direct peers
- Click Therapeutics: New York-based prescription digital therapeutics company that partners with pharma (e.g., Otsuka for depression) to develop FDA-cleared software-based treatments. Closely comparable business model, regulatory pathway, and GTM motion to Alex Therapeutics.
- GAIA AG: European (German) digital therapeutics company with CE-marked and DiGA-reimbured DTx products based on CBT and behavioral science. Direct peer on business model (pharma-licensed DTx), therapeutic modality (CBT), and geography/regulatory overlap (EU MDR/DiGA).
- Akili Interactive: US-based, FDA-authorized digital therapeutic focused on cognitive and behavioral health indications. Comparable on regulated SaMD status, FDA pathway, and prescription DTx category.
- Voluntis (Aptar Pharma): French digital therapeutics firm (now part of Aptar) that develops companion software for oncology and chronic disease drugs licensed to pharma. Direct peer on companion-app architecture, pharma partnership model, and oncology/rare-disease focus.
- Kaia Health: Digital therapeutics platform targeting chronic conditions (pain, COPD) using CBT-based therapy with AI personalization. Comparable technology stack (AI-personalized CBT) and pharma/B2B distribution angle.
- Big Health: Digital therapeutics company commercializing FDA-cleared CBT-based products for insomnia and anxiety. Comparable on CBT modality, behavioral-health focus, and clinical evidence-based positioning.
Regional players
- Orexo AB: Swedish specialty pharma with digital therapeutics initiatives for addiction and mental health, headquartered near Alex Therapeutics. Regional peer with overlapping therapy areas (smoking cessation) and shared Nordic regulatory familiarity.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Alex Therapeutics social profiles
Digital presenceAlex Therapeutics compliance and trust
Trust signalCompliance3 records
Alex Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alex Therapeutics leadership team
Management profileNumber of profiles
Profiles7 records
Alex Therapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alex Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alex Therapeutics
What does Alex Therapeutics do?
Alex Therapeutics develops and licenses an AI-powered digital therapeutics platform (the Alex DTx Platform) that combines evidence-based psychology — primarily Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) — with artificial intelligence and machine learning to deliver personalized Software as a Medical Device (SaMD) products. The company co-develops prescription digital therapeutics and companion apps with pharmaceutical partners such as Pfizer, Vicore Pharma, and Navamedic, focused on medication adherence, anxiety, nicotine cessation, Parkinson's, pulmonary fibrosis, and other cancer/rare-disease indications. Revenue is generated through B2B licensing, co-development, and commercialization agreements rather than direct-to-consumer sales.
Is Alex Therapeutics a public or private company?
Alex Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Alex Therapeutics founded?
Alex Therapeutics was founded in 2018. It employs 11 to 50 people.
Where is Alex Therapeutics based?
Alex Therapeutics is headquartered in Stockholm, Sweden, in the Europe region.
How does Alex Therapeutics make money?
Two revenue lines are on record. Platform Licensing to Pharma Partners are the primary driver. The others are digital Therapeutic Products.
Who are Alex Therapeutics's main competitors?
Emerging players on record are Limbic, BehaVR and Pear Therapeutics (legacy). Direct peers are Click Therapeutics, GAIA AG, Akili Interactive, Voluntis (Aptar Pharma), Kaia Health and Big Health. Orexo AB is listed as a regional player.
Does Alex Therapeutics have an API?
No public API is recorded for Alex Therapeutics.
What industry is Alex Therapeutics in?
Alex Therapeutics's product category is Digital Therapeutics. Its primary akta.pro industry code is HLACANAH, Therapeutic Companion Apps (Drug-Device-Digital Combination), with a secondary code of HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 513210 and its SIC code is 3841.